1. Name of Entity

Osteopore Limited (ABN 65 630 538 957)

Reporting Period	Half-year ended 30 June 2026
Previous Corresponding Reporting Period	Half-year ended 30 June 2025

2. Results for Announcement to Market

Financial results	**Up / Down**	**Change %**	**2026 $**	**2025 $ (Restated)**
Revenue from ordinary activities	Down	8	1,428,421	1,558,847
Loss after tax from ordinary activities attributable to members	Up	14	(2,012,559)	(1,760,272)
Loss attributable to members	Up	14	(2,012,559)	(1,760,272)

Final and interim dividends	It is not proposed that either a final or interim dividend be paid.
Record date for determining entitlements to the dividend	N/A
Brief explanation of any of the figures reported above	Revenue decreased by 8% year-on-year to $1,428,421 (30 June 2025: $1,558,847). On a constant currency basis, revenue was broadly consistent with the prior period, with the decrease in AUD terms largely attributable to the translation impact of a stronger Australian dollar against the currencies in which the Group transacts, primarily the US dollar, Korean won and Singapore dollar. In underlying currency terms, growth in the Philippines, Vietnam, Japan, the United States and Singapore was partially offset by lower sales in markets including India, Taiwan, the United Arab Emirates, the Netherlands and Thailand. In Europe, revenue was also affected by an extended clinical outcome verification process, standard for novel implant technologies entering new surgical centres, which has lengthened adoption timelines for Osteopore's custom cranial implants. Ongoing distribution transitions also contributing to lower sales during the period. The Group's net loss after tax for the half-year ended 30 June 2026 increased compared to the prior corresponding period. This primarily reflected higher product development and laboratory expenses, as the Company continued to invest in regulatory compliance activities to support its expanding product range and growing footprint across new geographies, as well as higher sales, marketing and business development expenses, reflecting continued investment in new market entry and distribution activities during the period. This was partially offset by lower administrative expenses during the period. Finance costs were $301,381 (30 June 2025: $276,467, restated), while the fair value loss on the embedded derivative associated with the Group's convertible notes was $41,718 (30 June 2025: $33,317, restated). The fair value loss is a non-cash item and does not affect the Group's underlying cash flow position.

3. Net Tangible Assets Backing per Ordinary Share	**Cents**
Net tangible assets/(liabilities) backing per ordinary share – current reporting period (30 June 2026)	(0.28)
Net tangible assets/(liabilities) backing per ordinary share – previous reporting period (31 December 2025) (Restated)	(0.76)

4. Control Gained Over Entities	
Details of entities over which control has been gained or lost	N/A

5. Dividends Paid and Payable	
Details of dividends or distribution payments	No dividends or distributions are payable.

6. Dividend Reinvestment Plans	
Details of dividend or distribution reinvestment plans	N/A

7. Details of Associates	
Details of associates and joint venture entities	N/A

8. Foreign Entities	
Foreign entities to disclose which accounting standards are used in compiling the report	All entities within the Group comply with International Financial Reporting Standards.

9. Review Opinion	
Details of any audit dispute or qualification	There are no audit disputes or qualifications to the review opinion.

Mark Leong
Executive Chairman
31 August 2026

Osteopore™

Empowering Natural Tissue Regeneration

OSTEOPORE LIMITED
AND ITS CONTROLLED ENTITIES

ACN 630 538 957

CONSOLIDATED HALF-YEAR FINANCIAL REPORT
FOR THE HALF-YEAR ENDED 30 JUNE 2026

CONTENTS

CORPORATE INFORMATION

Directors
Mark Leong
Lim Yujing
Professor Teoh Swee Hin
Michael Keenan

Company Secretary
Jack Rosagro

Registered Office / Principal Place of Business
Level 5, 191 St. Georges Terrace
Perth WA 6000

Telephone: +61 2 8072 1400

Share Register
Automic
Level 5, 126 Phillip Street
Sydney NSW 2000

Auditor
Pitcher Partners BA&A Pty Ltd
Level 11, 12 The Esplanade
Perth WA 6000

Website
https://www.osteopore.com/

DIRECTORS' REPORT

The Directors present their report, together with the condensed financial report of the consolidated entity consisting of Osteopore Limited ("Osteopore" or the "Company") and its controlled entities ("Group"), for the half-year ended 30 June 2026.

DIRECTORS

The names of Directors in office at any time during or since the end of the half-year ended 30 June 2026 were as follows:

Name	Position	Date Appointed	Date Resigned
Mark Leong	Executive Chairman	28 December 2021	—
Lim Yujing	Executive Director	24 September 2024	—
Professor Teoh Swee Hin	Non-Executive Director	24 June 2019	—
Michael Keenan	Non-Executive Director	18 July 2023	—

PRINCIPAL ACTIVITIES

Osteopore Limited is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to only allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants.

REVIEW OF OPERATIONS

Osteopore continued to progress its commercial and regulatory milestones during the period to 30 June 2026, notwithstanding an 8% decrease in revenue to $1,428,421, as compared to 30 June 2025 ($1,558,847). On a constant currency basis, revenue was broadly consistent with the prior period, with the decrease in AUD terms largely attributable to the translation impact of a stronger Australian dollar against the currencies in which the Group transacts, primarily the US dollar, Korean won and Singapore dollar. In underlying currency terms, growth in the Philippines, Vietnam, Japan, the United States and Singapore was partially offset by lower sales in markets including India, Taiwan, the United Arab Emirates, the Netherlands and Thailand. In Europe, revenue was also affected by an extended clinical outcome verification process, standard for novel implant technologies entering new surgical centres, which has lengthened adoption timelines for Osteopore's custom cranial implants. Ongoing distribution transitions also contributing to lower sales during the period.

Apart from reporting traction from approved business units, the Company has shown progress in obtaining market entry for new products, as well as progressing high-value collaborations as summarised below:

- Osteopore signed an exclusive license with Accelerate Technologies Pte Ltd, A*STAR's technology transfer arm, for an innovative technology that accelerates bone and tissue regeneration, positioning the Company to tap into the growing Asia Pacific market for bone growth factor therapies used in bone and tissue regeneration.
- Osteopore entered into a multi-year exclusive collaboration valued above RMB 12 million (approximately A$2.5 million) with Majeton Pte Ltd, a subsidiary of Hong Kong-listed Essex Bio-Technology Limited, to commercialise the Company's dental, orthodontic, and maxillofacial products in China, Hong Kong, and Macau. The first milestone payment of RMB 2.5 million (approximately A$520,000) was received in March 2026.

REVIEW OF OPERATIONS (CONTINUED)

- Osteopore expanded its orthopaedic business into Hong Kong through an exclusive distribution agreement with MontsMed Hong Kong Company Limited, focusing initially on the orthopaedic trauma reconstruction market. The first orthopaedic bone reconstruction case with a customised implant was successfully completed in June 2026.
- In partnership with Medprin Biotech GmbH, a subsidiary of Shenzhen-listed Medprin Regenerative Medical Technologies Co., Ltd, Osteopore signed an agreement to distribute its craniofacial products across Latin America, expanding the Company's regional access from Colombia to a 20-country region.
- Osteopore obtained regulatory market access for its orthopaedic portfolio in Malaysia, including its high tibial osteotomy solution and other bone grafting products. In partnership with DKSH Malaysia, Osteopore delivered its first dental products under their existing five-year distribution agreement.
- Osteopore secured approval from the Hainan Medical Products Administration to clinically use its orthopaedic custom devices at Shanghai Ruijin Hospital's Hainan branch, located within the Hainan Boao Lecheng International Medical Tourism Pilot Zone, enabling clinical use ahead of full mainland China approval.
- Osteopore's cleft lip augmentation clinical trial at Queensland Children's Hospital completed patient recruitment, with treatment of the first two patients now completed, and Osteopore's jaw reconstruction clinical trial at Princess Alexandra Hospital has successfully commenced.

RESULTS FOR THE PERIOD

The Group incurred a net loss after tax for the half-year ended 30 June 2026 of $2,012,559 (30 June 2025: $1,760,272). As at 30 June 2026, the Group recorded a net asset deficiency of $1,802,292 (31 December 2025: $1,970,130). Net operating cash outflows were $895,096 (30 June 2025: cash outflows of $1,275,507). The Group ends the half-year with a cash balance of $1,254,607 (31 December 2025: $626,972).

EVENTS SUBSEQUENT TO REPORTING PERIOD

On 23 July 2026, a convertible note with a total face value of $50,000 was converted into ordinary shares in the Company.

On 31 July 2026, the Board appointed Pitcher Partners BA&A Pty Ltd as auditor of the Company, following the resignation of Grant Thornton Audit Pty Ltd, with ASIC's consent under section 329(5) of the Corporations Act 2001. In accordance with section 327C of the Corporations Act 2001, this appointment will be put to shareholders for ratification at the Company's next Annual General Meeting.

On 6 August 2026, the Company entered into a 3-year distribution agreement with Al-Umnia Medical LLC for the distribution of its orthopaedic products across 5 countries in the Middle East: Saudi Arabia, United Arab Emirates, Oman, Qatar and Bahrain.

Apart from the above, no matter or circumstance has arisen since the end of the financial period which significantly affected or may significantly affect the operations of the Group, the results of those operations or the state of affairs of the Group in future financial periods.

AUDITOR'S INDEPENDENCE DECLARATION

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out immediately after this directors' report.

Signed in accordance with a resolution of the Directors.

Mark Leong
Executive Chairman
31 August 2026

AUDITOR'S INDEPENDENCE DECLARATION
TO THE DIRECTORS OF OSTEOPORE LIMITED
AND ITS CONTROLLED ENTITIES

In accordance with section 307C of the Corporations Act 2001, I declare to the best of my knowledge and belief in relation to the review of the financial report of Osteopore Limited and its Controlled Entities for the half-year ended 30 June 2026, there have been:

(i) No contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and

(ii) No contraventions of the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* in relation to the review.

PITCHER PARTNERS BA&A PTY LTD

PITCHER PARTNERS BA&A PTY LTD

MICHAEL LIPRINO
Executive Director
Perth, 31 August 2026

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE HALF-YEAR ENDED 30 JUNE 2026

	Note	Half-year 30 June 2026 $	30 June 2025 (RESTATED) $
Revenue	3	1,428,421	1,558,847
Cost of sales		(244,795)	(365,885)
Gross profit		**1,183,626**	**1,192,962**
Other income	4	29,565	57,636
Product development and laboratory expenses		(818,007)	(597,571)
Sales, marketing, and business development expenses		(711,888)	(607,770)
Administrative expenses		(819,947)	(968,103)
Other expenses		(399,125)	(410,349)
Share-based payments	11	(110,425)	(115,597)
Operating loss		**(1,646,201)**	**(1,448,792)**
Finance costs		(301,381)	(276,467)
Fair value loss on derivatives	8	(41,718)	(33,317)
Loss before income tax		**(1,989,300)**	**(1,758,576)**
Income tax expenses		(23,259)	(1,696)
Loss after income tax		**(2,012,559)**	**(1,760,272)**
Other comprehensive income/(loss)			
Exchange differences arising from the translation of foreign subsidiary		43,978	(144,801)
Total comprehensive loss, net of tax		**(1,968,581)**	**(1,905,073)**
Basic and diluted loss per share (cents)	12	(0.38)	(1.26)

The accompanying notes form part of this financial report.

**See Note 16 for details regarding the impact of restatement of previously issued financial statements*

CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 30 JUNE 2026

	Note	30 June 2026 $	31 December 2025 (RESTATED) $
ASSETS			
Current Assets			
Cash and cash equivalents		1,254,607	626,972
Trade receivables	5	1,069,220	1,046,301
Other assets	6	417,295	554,761
Inventories		439,906	362,856
Total Current Assets		**3,181,028**	**2,590,890**
Non-Current Assets			
Property, plant and equipment		87,996	84,950
Right-of-use asset		65,881	98,450
Intangible assets	7	53,869	-
Total Non-Current Assets		**207,746**	**183,400**
TOTAL ASSETS		**3,388,774**	**2,774,290**
LIABILITIES			
Current Liabilities			
Trade and other payables		2,317,368	1,712,000
Borrowings		-	47,287
Financial liabilities	8	2,701,160	2,791,586
Provisions		98,152	85,529
Lease liabilities		65,854	64,523
Total Current Liabilities		**5,182,534**	**4,700,925**
Non-Current Liabilities			
Lease liabilities		8,532	43,495
Total Non-Current Liabilities		**8,532**	**43,495**
TOTAL LIABILITIES		**5,191,066**	**4,744,420**
NET LIABILITIES		**(1,802,292)**	**(1,970,130)**
EQUITY			
Issued capital	9	36,410,169	34,313,675
Reserves	10	(14,183,106)	(14,267,009)
Accumulated losses		(24,029,355)	(22,016,796)
TOTAL DEFICIENCY		**(1,802,292)**	**(1,970,130)**

The accompanying notes form part of this financial report.

**See Note 16 for details regarding the impact of restatement of previously issued financial statements*

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE HALF-YEAR ENDED 30 JUNE 2026

	Note	Issued Capital $	Share Based Payment Reserve $	Common Control Reserve $	Foreign Currency Translation Reserve $	Accumulated Losses $	Total Equity $
Balance at 1 January 2025		**32,600,120**	**908,149**	**(14,915,451)**	**(220,536)**	**(18,066,062)**	**306,220**
Loss after income tax (restated)	16	-	-	-	-	(1,760,272)	(1,760,272)
Other comprehensive loss		-	-	-	(144,801)	-	(144,801)
Total comprehensive loss for the period (restated)	16	-	-	-	(144,801)	(1,760,272)	(1,905,073)
Shares placement	9	50,000	-	-	-	-	50,000
Shares conversion (restated)	9	883,781	-	-	-	-	883,781
Share-based payments (restated)		-	115,597	-	-	-	115,597
Employee share scheme – shares issued		56,963	(56,963)	-	-	-	-
Balance as restated at 30 June 2025		**33,590,864**	**966,783**	**(14,915,451)**	**(365,337)**	**(19,826,334)**	**(549,475)**
Balance as restated at 1 January 2026	16	**34,313,675**	**974,784**	**(14,915,451)**	**(326,342)**	**(22,016,796)**	**(1,970,130)**
Loss after income tax		-	-	-	-	(2,012,559)	(2,012,559)
Other comprehensive income		-	-	-	43,978	-	43,978
Total comprehensive income/(loss) for the period		-	-	-	43,978	(2,012,559)	(1,968,581)
Exercise of options	9	887	-	-	-	-	887
Shares conversion	9	2,025,107	-	-	-	-	2,025,107
Share-based payments	10	-	39,925	-	-	-	39,925
Employee share scheme – shares issued	10	70,500	-	-	-	-	70,500
Balance as at 30 June 2026		**36,410,169**	**1,014,709**	**(14,915,451)**	**(282,364)**	**(24,029,355)**	**(1,802,292)**

The accompanying notes form part of this financial report.

**See Note 16 for details regarding the impact of restatement of previously issued financial statements*

CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE HALF-YEAR ENDED 30 JUNE 2026

	Note	Half-year 30 June 2026 $	30 June 2025 (RESTATED) $
Cash flows from operating activities			
Loss before income tax		(1,989,300)	(1,758,576)
Adjustments for			
Amortisation expense		2,320	186,056
Allowance for expected credit loss		260,847	137,612
Depreciation (Property, plant, and equipment)		25,236	55,695
Depreciation (Right-of-use asset)		28,978	30,986
Finance costs		301,381	276,467
Fair value loss on derivatives	8	41,718	33,317
Interest income		(3,163)	(2,706)
Share-based payment expense		110,425	115,597
Property, plant and equipment written off		399	-
Operating cash flows before changes in working capital		(1,221,159)	(925,552)
Changes in trade receivables		(266,993)	(311,283)
Changes in other assets		173,453	(51,050)
Changes in inventories		(77,050)	40,843
Changes in trade and other payables		476,051	(33,957)
Changes in provisions		12,623	2,846
Interest paid		-	(60)
Interest received		3,163	2,706
Income tax refunded		4,816	-
Net cash used in operating activities		**(895,096)**	**(1,275,507)**
Cash flows from investing activities			
Purchases of plant and equipment		(27,138)	(4,443)
Loan to other entity		(44,969)	-
Net cash used in investing activities		**(72,107)**	**(4,443)**
Cash flows from financing activities			
Proceeds from exercise of share options		887	-
Repayment of borrowing		(47,287)	(1,163,316)
Proceeds from issue of convertible debt securities		1,750,000	4,000,000
Transaction costs for the issue of convertible debt securities		(105,000)	(240,000)
Repayment of lease principal		(29,711)	(27,510)
Interest paid		(3,237)	(4,922)
Net cash generated from financing activities		**1,565,652**	**2,564,252**
Net increase in cash and cash equivalents		598,449	1,284,302
Cash and cash equivalents at the beginning of the half-year		626,972	638,498
Effects of exchange rate changes on cash		29,186	(149,044)
Cash and cash equivalents at the end of the half-year		**1,254,607**	**1,773,756**

The accompanying notes form part of this financial report

CONDENSED NOTES TO THE CONSOLIDATED HALF-YEAR FINANCIAL REPORT

NOTE 1: MATERIAL ACCOUNTING POLICY INFORMATION

General Information and Basis of Preparation

The half-year financial report has been prepared in accordance with the requirements of the *Corporations Act 2001*, applicable accounting standards including AASB 134 *Interim Financial Reporting*. Accounting Interpretations and other authoritative pronouncements of the Australian Accounting Standards Board. Compliance with AASB 134 ensures compliance with IAS 34 'Interim Financial Reporting'.

The half-year financial report presents condensed consolidated financial statements for the half-year ended 30 June 2026 and does not include all the notes of the type usually included in an annual financial report. Accordingly, we recommend that this half-year financial report be read in conjunction with the annual report for the year ended 31 December 2025 and any public announcements made by the Group during the half-year reporting period in accordance with the continuous disclosure requirements of the *Corporations Act 2001*.

The half-year financial report has been approved and authorised for issue by the Board of Directors on 31 August 2026.

The accounting policies applied in this half-year financial report are consistent with those of the annual financial report for the year ended 31 December 2025.

Going Concern Assumption

The half-year financial report has been prepared on the going concern basis, which assumes continuity of normal business activities and the realisation of assets and the settlement of liabilities in the ordinary course of business.

The Directors note that the Group has net asset deficiency of $1,802,292 as of 30 June 2026, incurred a net loss for the half-year of $2,012,559 and net operating cash outflow of $895,096 for the period ended 30 June 2026. The Group has cash and cash equivalents as of 30 June 2026 of $1,254,607.

The net asset deficiency is primarily attributable to the outstanding redeemable convertible notes with an aggregate face value of approximately $2.45 million as of 30 June 2026. These notes are redeemable by the Company in cash or convertible into ordinary shares by the subscriber. Subsequent to the reporting date, a convertible note with a face value of $50,000 was converted into ordinary shares.

The Company's ability to continue as a going concern and to pay its debts as and when they fall due is dependent on the Company generating additional revenues from its operations, managing all costs in line with management's forecasts, continuing to draw down further funds under the convertible note subscription agreement and, if necessary, raising further capital. Management has prepared a cash flow forecast on this basis which indicates that the Consolidated Entity will have sufficient cash flows to meet minimum operating overheads and committed expenditure requirements for the 12-month period from the date of signing the financial report if they are successful in meeting those forecasts.

CONDENSED NOTES TO THE CONSOLIDATED HALF-YEAR FINANCIAL REPORT

NOTE 1: MATERIAL ACCOUNTING POLICY INFORMATION (CONTINUED)

Going Concern Assumption (Continued)

The Directors believe the Group will continue as a going concern, after consideration of the following factors:

- The Company entered into a subscription agreement on 24 December 2024 with Advance Opportunities Fund and Advance Opportunities Fund I ("AOF") for provision of redeemable convertible notes amounting in aggregate to a sum of up to $20,000,000;
- The Directors expect that AOF will continue to agree to the drawdown of further funds during the forecast period.
- Directors undertake regular review of management accounts and cash flow forecast, incorporating expected cash inflows from sales and collection of trade receivables;
- There is ongoing close management of both its operating costs and corporate overheads;
- The sales pipeline continues to grow and the Company is confident of achieving further sales growth;
- The Group has the ability to be successful in securing additional funds through further debt or equity issues as and when the need to raise working capital arises.

The financial report has therefore been prepared on a going concern basis. Should the Group be unable to achieve successful outcomes in relation to each of the matters referred to above, there is a material uncertainty whether the Group will be able to continue as a going concern and, therefore, whether they will realise their assets and discharge their liabilities in the normal course of business. The financial report does not include adjustments relating to the recoverability and classification of recorded asset amounts, nor to the amounts and classification of liabilities that might be necessary should the Group not continue as a going concern.

New, Revised or Amended Accounting Standards and Interpretations
During the period, the Directors have reviewed all the new and revised Standards and Interpretations issued by the AASB that are relevant to the Group and effective for the half-year reporting periods beginning on or after 1 January 2026. Accounting pronouncements which have become effective from 1 January 2026 and that have been adopted, do not have a significant impact on the Group's financial results or position.

When preparing the half-year financial report, management undertakes a number of judgements, estimates and assumptions about recognition and measurement of assets, liabilities, income and expenses. The actual results may differ from the judgements, estimates and assumptions made by management, and will seldom equal the estimated results.

The judgements, estimates and assumptions applied in the half-year financial report, including the key sources of estimation uncertainty, were the same as those applied in the Group's last annual financial statements for the year ended 31 December 2025.

CONDENSED NOTES TO THE CONSOLIDATED HALF-YEAR FINANCIAL REPORT

NOTE 2: DIVIDENDS

There have been no dividends declared or recommended and no distributions made to shareholders or other persons during the period.

NOTE 3. REVENUE

	Consolidated	
	30 June 2026	**30 June 2025**
	$	**$**
Sale of goods	1,428,421	1,558,847

All sale of goods is recognised at a point in time.

The Group's revenue disaggregated by primary geographical markets is as follows:

	30 June 2026	**30 June 2025**
	$	**$**
Vietnam	777,362	776,814
Philippines	223,401	155,919
Singapore	110,359	88,709
South Korea	104,344	112,769
Netherlands	42,180	77,778
Japan	41,540	13,365
United States	31,675	325
India	18,489	72,314
Malaysia	16,908	17,375
Taiwan	16,596	69,137
Other countries	45,567	174,342
	1,428,421	**1,558,847**

NOTE 4. OTHER INCOME

	Consolidated	
	30 June 2026	**30 June 2025**
	$	**$**
Bank interest income	3,163	2,706
Government grant	26,402	6,787
Foreign exchange gain	-	48,143
	29,565	**57,636**

CONDENSED NOTES TO THE CONSOLIDATED HALF-YEAR FINANCIAL REPORT

NOTE 5. TRADE RECEIVABLES

	Consolidated	
	30 June 2026 $	31 December 2025 $
Trade receivables	1,481,035	1,214,042
Less: expected credit losses	(411,815)	(167,741)
	1,069,220	**1,046,301**

NOTE 6. OTHER ASSETS

	Consolidated	
	30 June 2026 $	31 December 2025 $
Deposits	27,762	29,700
Prepayments	148,487	240,932
Other receivables	241,046	284,129
	417,295	**554,761**

NOTE 7. INTANGIBLE ASSETS

	Consolidated	
	30 June 2026 $	31 December 2025 $
Cost	1,109,974	1,090,544
Less: accumulated amortisation and impairment loss	(1,056,105)	(1,090,544)
	53,869	**-**
Cost		
Balance at the beginning of the period	1,090,544	1,108,470
Additions	55,691	-
Exchange rate movement	(36,261)	(17,926)
Balance at the end of the period	**1,109,974**	**1,090,544**
Accumulated amortisation and impairment loss		
Balance at the beginning of the period	1,090,544	646,608
Amortisation expense	2,320	370,814
Impairment loss	-	92,704
Exchange rate movement	(36,759)	(19,582)
Balance at the end of the period	**1,056,105**	**1,090,544**

CONDENSED NOTES TO THE CONSOLIDATED HALF-YEAR FINANCIAL REPORT

NOTE 8. FINANCIAL LIABILITIES

	Consolidated	
	30 June 2026	31 December 2025 (RESTATED)
	$	$
Convertible notes – host debt liability (amortised cost)	1,488,002	1,560,517
Convertible notes – derivative liability (FVTPL)	1,213,158	1,231,069
	2,701,160	**2,791,586**

During the period, the Company issued further convertible notes pursuant to a Subscription Agreement dated 24 December 2024. The facility provides up to $20,000,000 in funding, structured across four tranches of $5,000,000, with each tranche comprising 20 sub-tranches of $250,000.

Key Terms:
Facility Size: Up to $20,000,000, divided into four tranches of $5,000,000 each.
Sub-tranches: Each tranche comprises 20 sub-tranches of $250,000.
Face Value: Each note issued has a face value of $50,000.
Interest: 4.0% per annum, payable quarterly in arrears.
Maturity: 36 months from the T1 Closing Date (February 2025), expiring February 2028.
Conversion Rights: Notes are convertible at any time up to seven business days prior to maturity at a price equal to 80% of the 5-day VWAP of the Company's shares, with the 5-day period selected by the noteholder within the 45 business days prior to conversion. This results in the issue of a variable number of shares.
Mandatory Conversion: Any notes not redeemed or converted by maturity are mandatorily converted into shares.
Redemption Rights:

- At Company election – redeemable at 115% of principal plus accrued interest.
- If conversion is prohibited due to legal/regulatory restrictions – redeemable at 108% of principal plus accrued interest.
- In event of default – redeemable at 118% of principal plus default interest at 3% per month.

Covenants: The notes are subject to covenants including compliance with ASX listing rules, disclosure obligations, and shareholder approvals.
Fair Value Measurement:

- The embedded derivative is measured at fair value through profit or loss in accordance with AASB 9 Financial Instruments. The fair value measurement is classified as Level 3 within the fair value hierarchy in accordance with AASB 13 Fair Value Measurement, as the valuation requires the use of significant unobservable inputs.
- The fair value of the embedded derivative has been determined using a Monte Carlo simulation valuation methodology, which incorporates the probability-weighted outcomes of the conversion features embedded within the convertible notes. The model considers the contractual conversion mechanics and simulates a range of potential future share price paths to estimate the fair value of the conversion option at the reporting date.
- Key inputs used in the valuation include the Company's share price at the reporting date, expected share price volatility, risk-free interest rate, expected term of the notes and assumptions relating to conversion behaviour under the contractual terms of the notes.
- The valuation of the embedded derivative is sensitive to changes in key assumptions, particularly the Company's share price, expected share price volatility and the expected timing of conversion. A reasonably possible increase or decrease in these inputs would result in a corresponding increase or decrease in the fair value of the derivative liability.

**See Note 16 for details regarding the impact of restatement of previously issued financial statements*

CONDENSED NOTES TO THE CONSOLIDATED HALF-YEAR FINANCIAL REPORT

NOTE 8. FINANCIAL LIABILITIES (CONTINUED)

At each drawdown date, the fair value of the embedded derivative is determined, with the residual allocated to the host debt liability. The derivative is then remeasured to fair value at each reporting date, as follows

	Host Debt Liability	Derivative Liability	Total
	$	$	$
Balance at 1 January 2026 (Restated)	1,560,517	1,231,069	2,791,586
Recognised on drawdowns	837,782	858,743	1,696,525
Effective interest expense	246,619	-	246,619
Coupon accrued to interest payable	(50,181)	-	(50,181)
Conversions to equity	(1,106,735)	(918,372)	(2,025,107)
Fair value remeasurement	-	41,718	41,718
Balance at 30 June 2026	**1,488,002**	**1,213,158**	**2,701,160**

NOTE 9. ISSUED CAPITAL

	30 June 2026		31 December 2025 (RESTATED)	
	No. of Shares	$	No. of Shares	$
Fully paid ordinary shares	678,441,399	36,410,169	272,501,807	34,313,675

Movements in ordinary share capital

	No. of Shares	Issue/ conversion price ($)	$
Balance at 31 December 2024	**116,801,137**		**32,600,120**
Issuance of shares on 14 February 2025[2]	1,567,398	0.032	50,000
Shares conversion on 10 March 2025[3]	2,500,000	0.020	48,447
Shares conversion on 9 April 2025[3]	19,480,519	0.015	293,320
Shares conversion on 23 April 2025[3]	5,376,344	0.019	97,290
Shares conversion on 28 April 2025[3]	6,493,506	0.015	98,675
Shares conversion on 6 May 2025[3]	10,869,565	0.014	146,528
Issuance of shares on 7 May 2025[1]	2,000,000	0.019	38,000
Issuance of shares on 8 May 2025[1]	526,754	0.036	18,963
Shares conversion on 8 May 2025[3]	7,812,500	0.013	98,977
Shares conversion on 19 June 2025[3]	9,615,384	0.010	100,544
Shares conversion on 14 July 2025[3]	24,096,385	0.008	202,670
Shares conversion on 31 July 2025[3]	30,120,481	0.008	254,705
Shares conversion on 19 November 2025[3]	18,292,682	0.008	158,791
Shares conversion on 11 December 2025[3]	16,949,152	0.006	106,645
Balance at 31 December 2025 (RESTATED)	**272,501,807**		**34,313,675**

**See Note 16 for details regarding the impact of restatement of previously issued financial statements*

CONDENSED NOTES TO THE CONSOLIDATED HALF-YEAR FINANCIAL REPORT

NOTE 9. ISSUED CAPITAL (CONTINUED)

	No. of Shares	Issue/ conversion price ($)	$
Balance at 31 December 2025 (RESTATED)	**272,501,807**		**34,313,675**
Shares conversion on 9 January 2026[3]	10,000,000	0.005	53,845
Shares conversion on 16 January 2026[3]	50,000,000	0.005	242,553
Shares conversion on 20 January 2026[3]	10,000,000	0.005	54,060
Shares conversion on 27 January 2026[3]	20,000,000	0.005	108,380
Shares conversion on 30 January 2026[3]	20,000,000	0.005	108,491
Shares conversion on 3 February 2026[3]	50,000,000	0.005	271,602
Shares conversion on 11 February 2026[3]	50,000,000	0.005	271,197
Shares conversion on 3 March 2026[3]	30,000,000	0.005	143,436
Shares conversion on 5 March 2026[3]	50,000,000	0.005	239,288
Exercise of options on 7 April 2026	22,926	0.039	887
Shares conversion on 30 April 2026[3]	52,083,333	0.005	277,917
Issuance of shares on 11 May 2026[1]	11,750,000	0.006	70,500
Shares conversion on 5 June 2026[3]	52,083,333	0.005	254,338
Balance at 30 June 2026	**678,441,399**		**36,410,169**

[1] This refers to the issuance of shares under Employee Securities Incentive Plan.
[2] This refers to the issuance of commitment shares in accordance with the terms of the subscription agreement (Subscription Agreement) with Advance Opportunities Fund and Advance Opportunities Fund I.
[3] This refers to the conversion of redeemable convertible notes in accordance with the terms of the Subscription Agreement. For convertible note conversions, the amount recognised in issued capital represents the carrying amounts of the host debt and embedded derivative liabilities derecognised upon conversion. Accordingly, the amount recognised in issued capital may differ from the number of shares issued multiplied by the conversion price.

**See Note 16 for details regarding the impact of restatement of previously issued financial statements*

CONDENSED NOTES TO THE CONSOLIDATED HALF-YEAR FINANCIAL REPORT

NOTE 10. RESERVES

	Consolidated	
	30 June 2026	31 December 2025 (RESTATED)
	$	$
Common control reserve	(14,915,451)	(14,915,451)
Share based payment reserve	1,014,709	974,784
Foreign currency translation reserve	(282,364)	(326,342)
	(14,183,106)	**(14,267,009)**

Share based payment reserve

	No. of Options & Performance Rights	$
Share-based payment reserve as at 30 June 2026	**11,785,000**	**1,014,709**
Movements in share-based payment reserve		
Balance at 1 January 2026 (RESTATED)	**28,414,133**	**974,784**
Share-based payments – Director performance rights	-	39,925
Exercised during the period	(22,926)	-
Expired options	(16,606,207)	-
Balance at 30 June 2026	**11,785,000**	**1,014,709**

NOTE 11. SHARE BASED PAYMENT EXPENSE

Options

The following table illustrates the number and weighted average exercise price and movements in share options:

	30 June 2026		31 December 2025	
	Number	Weighted average exercise price $	Number	Weighted average exercise price $
Outstanding at the beginning of the period	16,629,133	0.74	16,641,633	0.75
Expired options	(3,510,164)	(3.38)	(12,500)	9.36
Expired options	(13,096,043)	(0.04)	-	-
Exercised during the period	(22,926)	(0.04)	-	-
Outstanding at the end of the period	-	-	16,629,133	0.74
Exercisable at the end of the period	**-**	**-**	**16,629,133**	**0.74**

**See Note 16 for details regarding the impact of restatement of previously issued financial statements*

CONDENSED NOTES TO THE CONSOLIDATED HALF-YEAR FINANCIAL REPORT

NOTE 11. SHARE BASED PAYMENT EXPENSE (CONTINUED)

Director Performance Rights

The fair value of the director performance rights issued during the financial year ended 31 December 2024 was estimated at the date of grant using the Monte Carlo valuation methodology. Details of the performance rights are set out below:

	Tranche A	Tranche B	Tranche C	Tranche D	Tranche E
Grant Date	23 Dec 2024	23 Dec 2024	23 Dec 2024	23 Dec 2024	23 Dec 2024
Expiry Date	23 Dec 2029	23 Dec 2029	23 Dec 2029	23 Dec 2029	23 Dec 2029
Share Price at Grant Date ($)	0.036	0.036	0.036	0.036	0.036
Number of Performance Rights	2,325,000	2,325,000	2,325,000	2,325,000	2,325,000
VWAP Hurdle ($)	0.077	0.115	0.154	0.192	0.231

For the financial period ended 30 June 2026, a total share-based payment expense of $110,425 (30 June 2025 Restated: $115,597) was recognised through profit and loss.

NOTE 12. LOSS PER SHARE

	Consolidated	
	30 June 2026	30 June 2025 (RESTATED)
	$	$
Loss after income tax	(2,012,559)	(1,760,272)
	No. of Shares	No. of Shares
Weighted average number of ordinary shares used in calculating basic and diluted loss per share	529,234,362	139,557,086
	Cents	Cents
Basic and diluted loss per share	(0.38)	(1.26)

As the Group incurred a loss for the period, any options on issue would have an anti-dilutive effect and therefore the diluted EPS is equal to the basic EPS. As at 30 June 2026, there were no options on issue (2025: 16,641,633). The share options outstanding in the comparative period have been excluded from the diluted EPS calculation as their effect was anti-dilutive.

**See Note 16 for details regarding the impact of restatement of previously issued financial statements*

CONDENSED NOTES TO THE CONSOLIDATED HALF-YEAR FINANCIAL REPORT

NOTE 13. SEGMENT REPORTING

The Group has identified its operating segments based on the internal reports that are used by the Board in assessing performance and in determining the allocation of resources. Given the Group's operations since incorporation, the Board has identified four relevant business segments based on the Group's geographical office – Singapore, Korea, China and Australia. The following tables are an analysis of the Group's revenue and results by reportable segment for the half-year ended 30 June 2026 and 2025.

Profit and Loss	Singapore $	Korea $	China $	Australia $	Elimination $	Consolidated $
30 June 2026						
Revenue from customers	863,948	563,100	-	1,373	-	1,428,421
Inter-segment revenue	227,758	-	-	-	(227,758)	-
Gross revenue	**1,091,706**	**563,100**	**-**	**1,373**	**(227,758)**	**1,428,421**
Other income	26,402	80	-	3,083	-	29,565
Total revenue	**1,118,108**	**563,180**	**-**	**4,456**	**(227,758)**	**1,457,986**
Loss for the half-year ended 30 June 2026	**(1,034,983)**	**(58,614)**	**(316)**	**(918,646)**	**-**	**(2,012,559)**
30 June 2025						
Revenue from customers	904,857	653,990	-	-	-	1,558,847
Inter-segment revenue	449,983	-	-	-	(449,983)	-
Gross revenue	**1,354,840**	**653,990**	**-**	**-**	**(449,983)**	**1,558,847**
Other income	182,550	(59,920)	-	(64,994)	-	57,636
Total revenue	**1,537,390**	**594,070**	**-**	**(64,994)**	**(449,983)**	**1,616,483**
(Loss)/profit for the half-year ended 30 June 2025	**(939,437)**	**264,376**	**(311)**	**(1,084,900)**	**-**	**(1,760,272)**

Financial Position	Singapore $	Korea $	China $	Australia $	Elimination $	Consolidated $
30 June 2026						
Current assets	1,227,430	1,155,322	814	797,462	-	3,181,028
Non-current assets	207,746	-	-	-	-	207,746
Total assets	**1,435,176**	1,155,322	**814**	**797,462**	-	**3,388,774**
Total liabilities	**(1,498,449)**	**(82,595)**	**-**	**(3,610,022)**	-	**(5,191,066)**
31 December 2025						
Current assets	1,067,843	1,324,910	1,137	197,000	-	2,590,890
Non-current assets	183,400	-	-	-	-	183,400
Total assets	**1,251,243**	**1,324,910**	**1,137**	**197,000**	-	**2,774,290**
Total liabilities	**(878,373)**	**(53,061)**	**-**	**(3,812,986)**	-	**(4,744,420)**

CONDENSED NOTES TO THE CONSOLIDATED HALF-YEAR FINANCIAL REPORT

NOTE 14. CONTINGENT ASSETS AND LIABILITIES

The Directors of the Group are not aware of any contingent liabilities which require disclosure in the financial period ended 30 June 2026 (2025: nil).

NOTE 15. EVENTS SUBSEQUENT TO REPORTING PERIOD

On 23 July 2026, a convertible note with a total face value of $50,000 was converted into ordinary shares in the Company.

On 31 July 2026, the Board appointed Pitcher Partners BA&A Pty Ltd as auditor of the Company, following the resignation of Grant Thornton Audit Pty Ltd, with ASIC's consent under section 329(5) of the Corporations Act 2001. In accordance with section 327C of the Corporations Act 2001, this appointment will be put to shareholders for ratification at the Company's next Annual General Meeting.

On 6 August 2026, the Company entered into a 3-year distribution agreement with Al-Umnia Medical LLC for the distribution of its orthopaedic products across 5 countries in the Middle East: Saudi Arabia, United Arab Emirates, Oman, Qatar and Bahrain.

Apart from the above, no matter or circumstance has arisen since the end of the financial period which significantly affected or may significantly affect the operations of the Group, the results of those operations or the state of affairs of the Group in future financial periods.

NOTE 16. PRIOR PERIOD RESTATEMENT

While preparing the half year financial report for the period ended 30 June 2026, the Group identified the following matters:

- The Group previously presented the host debt liability as a non-current liability for the year ended 31 December 2025. In accordance with AASB 2020-1, effective 1 January 2025, it was identified that this host debt liability should be presented as a current liability, given the classification of the derivative liability at 31 December 2025 is also current.

- The effective interest rate on the host debt component of the “AOF” and “AOF1” convertible notes as included in Note 8 of this half year financial report, were previously calculated with reference to the face value less transaction costs. It was noted that the effective interest rate should have been calculated using the initial host debt carrying amount on initial bifurcation under AASB 132. This resulted in an adjustment to finance costs and the carrying amount of the host debt liability.

- In accordance with AASB 2, the accounting for Tranches D and E of director’s performance rights was updated to appropriately expense the grant date fair value of the expected vesting period for these tranches. Separately, following Daniel Ow's resignation as a director on 29 May 2025, the accounting for his retained rights was revised to recognise the unamortised fair value in accordance with AASB 2.28(a).

As a result of the above matters, the following changes were noted to restate the comparative balances included in the 31 December 2025 Annual Report, and the half year financial report for the period ended 30 June 2025.

CONDENSED NOTES TO THE CONSOLIDATED HALF-YEAR FINANCIAL REPORT

NOTE 16. PRIOR PERIOD RESTATEMENT (CONTINUED)

Consolidated Statement of Profit or Loss and Other Comprehensive Income
For the half year ended 30 June 2025

	AS PREVIOUSLY REPORTED 30 JUNE 2025 $	*ADJUSTED 30 JUNE 2025 $*	RESTATED 30 JUNE 2025 $
Share-based payments	(92,869)	*(22,728)*	(115,597)
Operating loss	**(1,426,064)**	***(22,728)***	**(1,448,792)**
Finance costs	(174,115)	*(102,352)*	(276,467)
Fair value loss on derivatives	(26,065)	*(7,252)*	*(33,317)*
Loss before income tax	**(1,626,244)**	***(132,332)***	**(1,758,576)**
Loss after income tax	**(1,627,940)**	***(132,332)***	**(1,760,272)**
Total comprehensive loss, net of tax	**(1,772,741)**	***(132,332)***	**(1,905,073)**
Basic and diluted loss per share (cents)	(0.89)		(1.26)

Consolidated Statement of Financial Position
As at 31 December 2025

	AS PREVIOUSLY REPORTED 31 DECEMBER 2025 $	*ADJUSTED 31 DECEMBER 2025 $*	RESTATED 31 DECEMBER 2025 $
Liabilities			
Current Liabilities			
Trade and other payables	1,620,121	*91,879*	1,712,000
Financial liabilities	1,231,069	*1,560,517*	2,791,586
Total Current Liabilities	**3,048,529**	***1,652,396***	**4,700,925**
Non-Current Liabilities			
Financial liabilities	1,408,571	*(1,408,571)*	-
Total Non-Current Liabilities	**1,452,066**	***(1,408,571)***	**43,495**
TOTAL LIABILITIES	**4,500,595**	***243,825***	**4,744,420**
NET LIABILITIES	**(1,726,305)**	***(243,825)***	**(1,970,130)**
Equity			
Issued capital	34,307,083	*6,592*	34,313,675
Reserves	(14,315,523)	*48,514*	(14,267,009)
Accumulated losses	(21,717,865)	*(298,931)*	(22,016,796)
TOTAL DEFICIENCY	**(1,726,305)**	***(243,825)***	**(1,970,130)**

DIRECTORS' DECLARATION

In the opinion of the Directors of Osteopore Limited and its controlled entities:

1. The financial statements and notes, as set out within this financial report, are in accordance with the *Corporations Act 2001* including:

   (a) complying with Accounting Standard AASB 134: Interim Financial Reporting and the Corporations Regulations 2001; and

   (b) giving a true and fair view of the Group's financial position as at 30 June 2026 and its performance for the half-year then ended.

2. There are reasonable grounds to believe that the Group will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Board of Directors made pursuant to Section 303(5)(a) of the *Corporations Act 2001*.

On behalf of the directors

Mark Leong
Executive Chairman
31 August 2026

OSTEOPORE LIMITED
ABN 65 630 538 957

INDEPENDENT AUDITOR'S REVIEW REPORT
TO THE MEMBERS OF OSTEOPORE LIMITED

Report on the Half-Year Financial Report

Conclusion

We have reviewed the half-year financial report of Osteopore limited ("the Company") and its controlled entities ("the Group"), which comprises the consolidated condensed statement of financial position as at 30 June 2026, the consolidated condensed statement of profit or loss and other comprehensive income, the consolidated condensed statement of changes in equity and the consolidated condensed statement of cash flows for the half-year ended on that date, and notes comprising material accounting policy information and other explanatory information, and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the accompanying half-year financial report of the Group does not comply with the *Corporations Act 2001* including:

(a) giving a true and fair view of the Group's financial position as at 30 June 2026 and of its performance for the half-year ended on that date; and

(b) complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

Basis for Conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the *Auditor's Responsibilities for the Review of the Financial Report* section of our report. We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* issued by the Accounting Professional and Ethical Standards Board's ("the Code") that are relevant to audits of the annual financial report of public interest entities in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Corporations Act 2001* which has been given to the directors of the Company, would be in the same terms if given to the directors as at the time of this auditor's review report.

Material Uncertainty Related to Going Concern

We draw attention to Note 1 to the half-year financial report, which indicates that the Group had a net asset deficiency of $1,802,292 as of 30 June 2026, incurred a net loss for the half-year of $2,012,559 and net operating cash outflow of $895,096 for the period ended 30 June 2026.

These conditions, along with other matters set forth in Note 1 to the half-year financial report, indicate that a material uncertainty exists that may cast significant doubt on the Group's ability to continue as a going concern. Our conclusion is not modified in this respect.

Emphasis of Matter – Restatement of comparative balances

We draw attention to Note 16 of the half-year financial report, which states that the amounts reported in the previously issued financial report as at 31 December 2025 and interim financial report for the half-year ended 30 June 2025 have been restated and disclosed as comparatives in this interim financial report. Our conclusion is not modified in respect of this matter.

OSTEOPORE LIMITED
ABN 65 630 538 957

INDEPENDENT AUDITOR'S REVIEW REPORT
TO THE MEMBERS OF OSTEOPORE LIMITED

Responsibilities of the Directors for the Financial Report

The directors of the Company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor's Responsibilities for the Review of the Financial Report

Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Group's financial position as at 30 June 2026 and its performance for the half-year ended on that date, and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

PITCHER PARTNERS BA&A PTY LTD

PITCHER PARTNERS BA&A PTY LTD

MICHAEL LIPRINO
Executive Director
Perth, 31 August 2026